Actively Recruiting
French Hypertrophic Cardiomyopathy Observatory
Led by French Cardiology Society · Updated on 2022-09-21
600
Participants Needed
1
Research Sites
987 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use. The purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)
CONDITIONS
Official Title
French Hypertrophic Cardiomyopathy Observatory
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 15 years or older
- Diagnosis of hypertrophic cardiomyopathy with left ventricle thickness ≥ 13 mm if familial or ≥ 15 mm if sporadic
You will not qualify if you...
- Expressed refusal to participate in the study
- Significant aortic stenosis (less than 1 cm squared)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
European Georges Pompidou Hospital
Paris, France, 75015
Actively Recruiting
Research Team
A
Albert Hagege
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here